Linzess: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 254 patients receiving stable opioid treatment for chronic non-cancer pain and who suffered from constipation showed that once-daily 145 and 290 ug oral linaclotide each met the primary endpoint of improving SBM frequency rate from baseline to week 8 vs. placebo. ...